Literature DB >> 25407133

An update on the use of botulinum toxin therapy in Parkinson's disease.

Reversa Mills1, Laxman Bahroo, Fernando Pagan.   

Abstract

Botulinum toxin (BoNT) has gained widespread use in a variety of neurological conditions. Parkinson's disease is a complex neurodegenerative disorder manifested by motor and non-motor symptoms that can cause significant disability. BoNT has been used to effectively treat a variety of symptoms related to Parkinson's disease. This review will examine the current therapeutic indications of BoNT use in the following disorders related to Parkinson's disease: cervical dystonia, blepharospasm and lid apraxia, focal hand dystonia, foot dystonia, laryngeal dystonia, oromandibular dystonia, camptocormia, hand and jaw tremor, sialorrhea, hyperhidrosis, dysphagia, constipation, and overactive bladder.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25407133     DOI： 10.1007/s11910-014-0511-3

Source DB:  PubMed          Journal:  Curr Neurol Neurosci Rep        ISSN： 1528-4042            Impact factor:   5.081


  82 in total

Review 1.  Botulinum toxin in clinical practice.

Authors:  J Jankovic
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-07       Impact factor: 10.154

2.  Autonomic function after botulinum toxin type A or B: a double-blind, randomized trial.

Authors:  R Tintner; R Gross; U F Winzer; K A Smalky; J Jankovic
Journal:  Neurology       Date:  2005-09-13       Impact factor: 9.910

3.  Botulinum toxin for writer's cramp: a randomised, placebo-controlled trial and 1-year follow-up.

Authors:  J J M Kruisdijk; J H T M Koelman; B W Ongerboer de Visser; R J de Haan; J D Speelman
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-12-21       Impact factor: 10.154

4.  Botulinum toxin and gastrointestinal tract disorders: panacea, placebo, or pathway to the future?

Authors:  Brian E Lacy; Kirsten Weiser; Abigail Kennedy
Journal:  Gastroenterol Hepatol (N Y)       Date:  2008-04

5.  Double-blind controlled study of botulinum toxin in adductor spasmodic dysphonia.

Authors:  D D Troung; M Rontal; M Rolnick; A E Aronson; K Mistura
Journal:  Laryngoscope       Date:  1991-06       Impact factor: 3.325

6.  Botulinum toxin type A for drooling in Parkinson's disease: a double-blind, randomized, placebo-controlled study.

Authors:  Giovanni Lagalla; Marzia Millevolte; Marianna Capecci; Leandro Provinciali; Maria Gabriella Ceravolo
Journal:  Mov Disord       Date:  2006-05       Impact factor: 10.338

7.  Outlet type constipation in Parkinson's disease: results of botulinum toxin treatment.

Authors:  F Cadeddu; A R Bentivoglio; F Brandara; G Marniga; G Brisinda; G Maria
Journal:  Aliment Pharmacol Ther       Date:  2005-11-15       Impact factor: 8.171

8.  Sweating dysfunction in Parkinson's disease.

Authors:  Lesley Swinn; Anette Schrag; Ramchandran Viswanathan; Bastiaan R Bloem; Andrew Lees; Niall Quinn
Journal:  Mov Disord       Date:  2003-12       Impact factor: 10.338

9.  Double-blind, placebo-controlled study to evaluate the efficacy and safety of botulinum toxin type A in the treatment of drooling in parkinsonism.

Authors:  Francesca Mancini; Roberta Zangaglia; Silvano Cristina; Maria Grazia Sommaruga; Emilia Martignoni; Giuseppe Nappi; Claudio Pacchetti
Journal:  Mov Disord       Date:  2003-06       Impact factor: 10.338

10.  Treatment of outlet obstruction constipation in Parkinson's disease with botulinum neurotoxin A.

Authors:  Alberto Albanese; Giuseppe Brisinda; Anna Rita Bentivoglio; Giorgio Maria
Journal:  Am J Gastroenterol       Date:  2003-06       Impact factor: 10.864
View more
  7 in total

Review 1.  Nondopaminergic treatments for Parkinson's disease: current and future prospects.

Authors:  Maria Eliza Freitas; Susan H Fox
Journal:  Neurodegener Dis Manag       Date:  2016-05-27

Review 2.  Oropharyngeal dysphagia: manifestations and diagnosis.

Authors:  Nathalie Rommel; Shaheen Hamdy
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2015-12-02       Impact factor: 46.802

Review 3.  Gastrointestinal Dysfunction in Parkinson's Disease.

Authors:  Delaram Safarpour; Kaveh Sharzehi; Ronald F Pfeiffer
Journal:  Drugs       Date:  2022-01-25       Impact factor: 9.546

4.  Occurrence of Dysphagia Following Botulinum Toxin Injection in Parkinsonism-related Cervical Dystonia: A Retrospective Study.

Authors:  Addie Patterson; Leonardo Almeida; Christopher W Hess; Daniel Martinez-Ramirez; Michael S Okun; Ramon L Rodriguez; Valerie Rundle-Gonzalez; Aparna Wagle Shukla; Irene A Malaty
Journal:  Tremor Other Hyperkinet Mov (N Y)       Date:  2016-11-03

5.  Heightened risk of early vocal fold motion impairment onset and dysphagia in the parkinsonian variant of multiple system atrophy: a comparative study.

Authors:  Kaoru Tsuchiya; Rumi Ueha; Sayaka Suzuki; Takao Goto; Taku Sato; Takaharu Nito; Tatsuya Yamasoba
Journal:  Clin Park Relat Disord       Date:  2020-01-16

6.  A Double-Blind Randomized Controlled Trial Investigating the Most Efficacious Dose of Botulinum Toxin-A for Sialorrhea Treatment in Asian Adults with Neurological Diseases.

Authors:  Mazlina Mazlan; Shivani Rajasegaran; Julia Patrick Engkasan; Ouzreiah Nawawi; Khean-Jin Goh; Saini Jeffery Freddy
Journal:  Toxins (Basel)       Date:  2015-09-22       Impact factor: 4.546

Review 7.  Therapeutic Applications of Botulinum Neurotoxin for Autonomic Symptoms in Parkinson's Disease: An Updated Review.

Authors:  Steven D Mitchell; Christos Sidiropoulos
Journal:  Toxins (Basel)       Date:  2021-03-19       Impact factor: 4.546
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.